S100A10 regulates tumor necrosis factor alpha-induced apoptosis in chondrocytes via the reactive oxygen species/nuclear factor-kappa B pathway

Aberrant chondrocyte apoptosis and inflammation are the most critical causes of osteoarthritis (OA) development. This study was designed to demonstrate the relationship between S100A10 and OA. In this study, S100A10 was overexpressed or silenced in rat chondrocytes. Cell viability, apoptosis, reactive oxidative species (ROS), and calcium ion detection were assessed using Cell Counting Kit-8 assay and flow cytometry. The levels of key oxidation-related enzymes and tumor necrosis factor-alpha (TNF-alpha) were quantified using enzyme-linked immunosorbent assay, quantitative polymerase chain reaction, andWestern blotting. S100A10 was highly expressed in patients with OA and positively correlated with TNF-alpha level. Knockdown of S100A10 effectively counteracted TNF-alpha-induced ROS level, apoptosis, and calcium level and associated with decreased inflammation-related metalloproteinase 1 (MMP1), MMP13, and nuclear necrosis factor-kappa B (NF-kappa B)-p65 and increased survivin and cytoplasmic NF-kappa B-p65. Overexpression of S100A10 had an effect similar to TNF-alpha, which was significantly counteracted by pyrrolidine dithiocarbamate, an NF-kappa B inhibitor, or verapamil, a calcium-channel blocker. S100A10 contributed to chondrocyte apoptosis through the ROS/NF-kappa B pathway. This study has established the relationship between S100A10 and the NF-kappa B pathway, thus providing novel perspectives for exploring S100A10 functions.